Alphabet, Editas and Bio Palette-backed genomic medicine developer Beam will raise $180m in an upsized initial public offering three years after being spun out of Harvard University.

Beam Therapeutics, a US-based genetic therapy developer backed by internet and technology group Alphabet, priced its shares at $17.00 each for a $180m initial public offering today. The company increased the number of shares in the offering from 9.25 million to nearly 10.6 million and is floatingĀ on the Nasdaq Global Select Market at the top…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.